10-12 December, 2018

London, UK

Day One
Tuesday, 11th December, 2018

Day Two
Wednesday, 12th December, 2018

08.00
Registration & Breakfast

08.50
Chair’s Opening Remarks

  • Arpita Maiti Senior Senior Director, External Science & Innovation, Inflammation, Immunology and Microbiome, Pfizer

Harnessing Tregs to Induce Antigen-Specific Immune Tolerance

09.00
Antigen-Specific Immunotherapy of Autoimmune Diseases

  • David Wraith Institute Director of Immunology & Immunotherapy and Professor of Immunology , University of Birmingham

Synopsis

  • Different approaches to antigen-specific immunotherapy with autoantigens have been designed
  • These generate immune suppression of disease through induction of distinct populations of regulatory T cells
  • Antigen-specific immunotherapy with soluble peptides has proven well tolerated with evidence of efficacy in different autoimmune conditions

09.30
Innovation in Restoring Immune Tolerance in Autoinflammatory Disease: Engineering CAR Regulatory T Cells

  • Céline Dumont Senior Director Preclinical Pharmacology and Safety, TxCell

Synopsis

  • Engineering CAR regulatory T cells as an alternative to antigen specific Tregs
  • CAR Tregs as a new modality to restore immune tolerance
  • Harnessing new potential activity of Tregs beyond their suppressive function to bring new medicine to patients

10.00
Leveraging Antigen-Specific Regulatory T Cell Responses to Defeat Type 1 Diabetes

  • José Carballido Executive Director of Institutes Biomedical Research, Novartis

Synopsis

  • Induction of autoantigen-specific regulatory T cells is a very promising mechanism to dampen polyclonal autoreactivity without impairing broad immune function
  • One single antigen specificity is required and sufficient to restore immune homeostasis
  • Precision, and not personalized, immunotherapy has the potential to solve the medical need in T1D

10.30
On Treg, IL-2 and Tolerance

  • David Klatzmann Director - Clinical Investigation Center for Biotherapy , Sorbonne University & Pitié-Salpêtrière Hospital

Synopsis

  • Understanding Treg specificity is key to understanding (antigen specific) tolerance
  • Low dose IL-2 stimulates and expands Tregs
  • Combined use of IL-2 and antigen could be an ultimate way to establish antigen specific tolerance

11.00
Speed Networking & Morning Refreshments

Validation of Antigen-Specific Targets: Benchmark Against the Latest Scope & Strategies

12.00
Accessing Innovation in Antigen-Specific Immune Tolerance – A Big Pharma View

  • Arpita Maiti Senior Senior Director, External Science & Innovation, Inflammation, Immunology and Microbiome, Pfizer

Synopsis

  • Antigen-specific immune tolerance will form the basis of future transformative therapies for autoimmune diseases that have the potential to be curative
  • Approaches/modalities to induce immune tolerance are complex and will require innovation across the drug development and commercialization pathway
  • Big pharma deploys multiple vehicles to access this innovation and augmenting it with in-house capabilities to bring new medicines to patients in need

12.30
Translating the Learnings from Allergen Immunotherapy for Inducing Long Term Antigen-Specific Tolerance

Synopsis

  • How to develop novel targeted treatments that induce antigen-specific tolerance with a long lasting effect in immune mediated disorders?
  • How to identify and validate disease-specific antigen targets, biomarkers and route of administration to translate these learnings into effective autoimmunity therapies for patients with immune mediated disorders?
  • Update on Allero Therapeutics efforts for demonstrating proof-of-principle in immune mediated disorders

13.00
Measuring and Limiting Antigen-Specific Immune Tolerance in Type 1 Diabetes

  • Mark Peakman Professor of Clinical Immunology- Faculty of Life Sciences & Medicine , King’s College London

Synopsis

  • Systematic approaches to epitope discovery
  • Highly sensitive diagnostic toolkits
  • Strategies for inducing immune tolerance

13.30
Networking Lunch

Advancing Pre-Clinical Development of Novel Antigen-Specific Immune Tolerance Therapies

14.30
TOL2: An Antigen Specific Tolerogenic Therapy for the Treatment of Myasthenia Gravis

Synopsis

  • TOL2 treatment modalities
  • Tolerance induction and maintenance using TOL2
  • Preclinical development of TOL2

15.00
Anti-IL7Ra Antibody: Next Generation Anti-Cytokine Therapy

Synopsis

  • OSE immunotherapeutics is developing novel immunotherapies targeting activation and regulation pathways of the immune system
  • Anti-IL7Ra mAb targets the fuel of effector and memory T lymphocytes while sparing regulatory T cells
  • Appropriate anti-IL7Ra mAb induce long-term and robust antigen-specific immune tolerance in non-human primate by clonal deletion of experienced anti-gen-specific memory T cells

15.30
Targeted Antigen Delivery to the Liver Via Synthetic Glycosylation Induces Robust Antigen-Specific Tolerance

Synopsis

  • Active targeting domains deliver antigen to tolerogenic pathways in the liver, and induce robust antigen-specific tolerance in both mouse and non-human primate models of immunity
  • Our technologies are translational, in that the mechanisms induced are consistent with unmet clinical needs, and our molecules are developable
  • Discuss potential approaches to de-risk MoA’s in higher-order species, and consider their value

16.00
Afternoon Refreshments & Networking

16.30
Roundtable Discussions:

Synopsis

Our breakout roundtables will allow you to have more intimate discussions with thought leaders of the field of autoimmunity around some of the hottest topics in the field. Discover multiple perspectives on these key issues, so that you can learn from your fellow experts in the audience. Drive your own learning, crowd-source ideas and get inspired. Immerse yourself in the following discussions:

  1. What is antigen-specific immune tolerance and do we know how to effectively measure it?
  2. How to identify and validate the right antigen(s) to be targeted in complex autoimmune diseases?
  3. What are the challenges and opportunities in developing durable antigen-specific immune tolerance both mechanistically and clinically?

17.00
Chair’s Closing Remarks & End of Day One